# COGT catalysts: Cogent Biosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cogt/catalysts

> Cogent Biosciences, Inc. (COGT) has 4 upcoming catalysts. The next is the bezuclastinib PDUFA date, November 30, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for COGT?

Cogent Biosciences, Inc. (COGT) has 4 upcoming catalysts. The next is the bezuclastinib PDUFA date, November 30, 2026. Press release filed with the SEC (EX-99): "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026" [Calendar and source filings](https://sec-api.dev/companies/cogt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-449926, https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/cogt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Cogent Biosciences, Inc. |
| Ticker | COGT (Nasdaq) |
| SEC CIK | 1622229 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cogt |

## Cash runway

Cash $791.1M as of 2026-09-30; quarterly burn $80.8M; about 29.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-449963).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2023 | [Bezuclastinib trial start](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "In April 2023, we initiated Part 2 of the APEX trial, the potentially registrational portion of the study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1622229/000119312525272334/cogt-20250930.htm)) |
| November 12, 2024 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., November 12, 2024 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/cogt-ex99_1.htm)) |
| February 25, 2025 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., February 25, 2025 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/cogt-ex99_1.htm)) |
| May 6, 2025 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "Cogent Biosciences Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/cogt-ex99_1.htm)) |
| May 22, 2025 | [Bezuclastinib tablets (formulation a) primary completion](https://sec-api.dev/pdufa/bezuclastinib-tablets-formulation-a) | COGT | SSM; Mastocytosis, Indolent; Mastocytosis, Systemic | completed | "NCT05186753 ((Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-22 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05186753)) |
| 2H 2025 | [Bezuclastinib topline data readout](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "Supported by our recent upsized public offering, Cogent is advancing our mission from a position of strength as we prepare to report top-line results from two additional pivotal trials in GIST and AdvSM in the second half of this year, submit our first New Drug Application by the end of 2025 and make continued progress toward the anticipated commercial launch of bezuclastinib in 2026."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-ex99_1.htm)) |
| July 7, 2025 | [Bezuclastinib topline data readout](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed, met | "On July 7, 2025, Cogent Biosciences, Inc. (the "Company") announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis ("NonAdvSM") demonstrating clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1622229/000119312525155811/d156610d8k.htm)) |
| August 5, 2025 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., August 5, 2025 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-ex99_1.htm)) |
| late 2025 | [Bezuclastinib NDA/BLA submission](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the company's expectation to report top-line results from both PEAK and APEX in the second half of 2025; the potential for bezuclastinib to become the new standard of care for NonAdvSM patients; the company's expectation to submit its first NDA by the end of 2025; the anticipated commercial launch of bezuclastinib in 2026; and the company's anticipated cash runway into 2027, including through potential FDA approval of bezuclastinib for NonAdvSM and early commercial launch activities." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-ex99_1.htm)) |
| late 2025 | [Bezuclastinib trial start](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "and the company's plans to initiate a Phase 1 trial for its ErbB2 program before the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm)) |
| September 19, 2025 | [Bezuclastinib primary completion](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "NCT04996875 ((Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04996875)) |
| September 30, 2025 | [Bezuclastinib primary completion](https://sec-api.dev/pdufa/bezuclastinib) | COGT | Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer | completed | "NCT05208047 ((Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Cogent Biosciences, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05208047)) |
| Nov 2025 | [Cogent Biosciences, Inc. topline data readout](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | scheduled | "We plan to present top line results in November 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1622229/000119312525272334/cogt-20250930.htm)) |
| Nov 2025 | [Bezuclastinib topline data readout](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed, positive | "In November 2025, announced topline results from the Phase 3 PEAK trial of bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib, becoming the first positive Phase 3 trial in second-line GIST patients in over 20 years." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm)) |
| Nov 2025 | [CGT4255 trial start](https://sec-api.dev/pdufa/cgt4255) | COGT |  | scheduled | "We recently received clearance from the FDA on our IND submission for CGT4255 and plan to initiate a Phase 1 clinical trial in November 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1622229/000119312525272334/cogt-20250930.htm)) |
| November 3, 2025 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., November 3, 2025 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-ex99_1.htm)) |
| December 6, 2025 | [Bezuclastinib topline data readout](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed, positive | "On December 6, 2025 and December 8, 2025, Cogent Biosciences, Inc. (the "Company") presented the full results from its SUMMIT clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis ("NonAdvSM") and announced positive top-line results from its APEX clinical trial of bezuclastinib in patients with advanced systemic mastocytosis ("AdvSM"), respectively." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1622229/000119312525311217/d81277d8k.htm)) |
| Jan 2026 | [Bezuclastinib NDA/BLA acceptance](https://sec-api.dev/pdufa/bezuclastinib) | COGT | NonAdvSM in December 2025 | completed | "We submitted our first NDA for bezuclastinib in patients with NonAdvSM in December 2025, which was accepted by the FDA in March 2026 and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526342683/d149476d424b5.htm)) |
| Jan 2026 | [Bezuclastinib NDA/BLA submission](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "We submitted the first New Drug Application ("NDA") for NonAdvSM in 2025; we initiated our NDA submission for GIST in January 2026 and expect to complete the submission in April 2026; and we plan to submit an NDA in AdvSM in the first half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-20251231.htm)) |
| February 17, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., February 17, 2026 -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm)) |
| Apr 2026 | [Bezuclastinib NDA/BLA submission](https://sec-api.dev/pdufa/bezuclastinib) | COGT | AdvSM | scheduled | "plans to complete the submission of an NDA for bezuclastinib in combination with sunitinib in patients with GIST in April 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526053131/cogt-ex99_1.htm)) |
| mid-2026 | [Bezuclastinib trial start](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "In mid-2026, we expect to initiate a Phase 2 trial investigating the benefit of the bezuclastinib plus sunitinib combination for first-line GIST patients with exon 9 mutations who are naive to, or recently initiated treatment with, imatinib." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205170/cogt-20260331.htm)) |
| May 5, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)) |
| May 5, 2026 | [Bezuclastinib NDA/BLA acceptance](https://sec-api.dev/pdufa/bezuclastinib) | COGT | NonAdvanced Systemic Mastocytosis | completed | "Announced the FDA accepted its NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526205124/cogt-ex99_1.htm)) |
| Jun 2026 | [Bezuclastinib NDA/BLA submission](https://sec-api.dev/pdufa/bezuclastinib) | COGT | AdvSM | completed | "In June 2026, we submitted our third NDA for bezuclastinib in patients with AdvSM." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526342683/d149476d424b5.htm)) |
| August 10, 2026 | [Bezuclastinib NDA/BLA acceptance](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "Announced FDA acceptance of the New Drug Application (NDA) with priority review for bezuclastinib in combination with sunitinib in patients with GIST who have received prior treatment with imatinib." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm)) |
| August 10, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., August 10, 2026 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm)) |
| November 5, 2026 | [Bezuclastinib NDA/BLA acceptance](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | completed | "Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| November 5, 2026 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., November 5, 2026 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| November 30, 2026 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| December 30, 2026 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT | NonAdvanced Systemic Mastocytosis | scheduled | "Potential FDA approval of bezuclastinib in NonAdvSM - PDUFA date of December 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| June 29, 2027 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "Potential FDA approval of bezuclastinib in AdvSM - PDUFA date of June 29, 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| late 2028 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into late 2028, well past all three pending PDUFA action dates for bezuclastinib." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |

## Drugs

- [Bezuclastinib](https://sec-api.dev/pdufa/bezuclastinib): advsm, nonadvanced systemic mastocytosis, nonadvsm in december 2025, gist in april 2026, advsm demonstrating clinically meaningful results as measured, non-advanced systemic mastocytosis, Advanced Systemic Mastocytosis (AdvSM), Advanced Gastrointestinal Stromal Tumors
- [Bezuclastinib tablets (formulation a)](https://sec-api.dev/pdufa/bezuclastinib-tablets-formulation-a): SSM
- [CGT4255](https://sec-api.dev/pdufa/cgt4255): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cogt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "COGT catalysts: Cogent Biosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cogt/catalysts

```bibtex
@misc{secapidev_companies_cogt_catalysts_20261116,
  title        = {COGT catalysts: Cogent Biosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cogt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cogt_catalysts_20261116","title":"COGT catalysts: Cogent Biosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cogt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
